Amicus Therapeutics, Inc. Announces Unaudited Preliminary Revenue Results for the Fourth Quarter and Full Year of 2023
January 07, 2024 at 04:00 pm EST
Share
Amicus Therapeutics, Inc. announced unaudited preliminary revenue results for the fourth quarter and full year of 2023. Fourth quarter total revenue was ~$115.1 million. Galafold (migalastat) net product sales in 2023 were ~$387.8 million, representing a year-over-year increase of 18%, or 17% at CER. Fourth quarter Galafold net product sales were ~$106.6 million.
Total revenue in 2023 reached ~$399.4 million, representing a year-over-year increase of 21%, reflecting strong operational growth measured at constant exchange rates (CER) of 20% and a favorable currency impact of approximately $2.7 million, or 1%.
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
AMICUS THERAPEUTICS, INC. 
